299 related articles for article (PubMed ID: 33624556)
21. Hypoxia-induced acute lung injury in murine models of sickle cell disease.
Pritchard KA; Ou J; Ou Z; Shi Y; Franciosi JP; Signorino P; Kaul S; Ackland-Berglund C; Witte K; Holzhauer S; Mohandas N; Guice KS; Oldham KT; Hillery CA
Am J Physiol Lung Cell Mol Physiol; 2004 Apr; 286(4):L705-14. PubMed ID: 12972407
[TBL] [Abstract][Full Text] [Related]
22. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
Morris CR; Kato GJ; Poljakovic M; Wang X; Blackwelder WC; Sachdev V; Hazen SL; Vichinsky EP; Morris SM; Gladwin MT
JAMA; 2005 Jul; 294(1):81-90. PubMed ID: 15998894
[TBL] [Abstract][Full Text] [Related]
23. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Lopes FC; Traina F; Almeida CB; Leonardo FC; Franco-Penteado CF; Garrido VT; Colella MP; Soares R; Olalla-Saad ST; Costa FF; Conran N
Haematologica; 2015 Jun; 100(6):730-9. PubMed ID: 25769545
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease.
Schnog JB; Teerlink T; van der Dijs FP; Duits AJ; Muskiet FA;
Ann Hematol; 2005 May; 84(5):282-6. PubMed ID: 15599544
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a metabolic shift of arginine metabolism in sickle cell disease.
Schnog JJ; Jager EH; van der Dijs FP; Duits AJ; Moshage H; Muskiet FD; Muskiet FA
Ann Hematol; 2004 Jun; 83(6):371-5. PubMed ID: 15054669
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide production from hydroxyurea.
King SB
Free Radic Biol Med; 2004 Sep; 37(6):737-44. PubMed ID: 15304249
[TBL] [Abstract][Full Text] [Related]
27. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.
Nahavandi M; Tavakkoli F; Wyche MQ; Perlin E; Winter WP; Castro O
Br J Haematol; 2002 Dec; 119(3):855-7. PubMed ID: 12437671
[TBL] [Abstract][Full Text] [Related]
29. A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.
Zhang X; Shah BN; Zhang W; Saraf SL; Miasnikova G; Sergueeva A; Ammosova T; Niu X; Nouraie M; Nekhai S; Castro O; Gladwin MT; Prchal JT; Garcia JG; Machado RF; Gordeuk VR
Hum Mol Genet; 2016 Oct; 25(20):4601-4609. PubMed ID: 28173069
[TBL] [Abstract][Full Text] [Related]
30. Arginine metabolism and nitric oxide bioavailability in sickle cell disease.
Jain S; Gladwin MT
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e247-8. PubMed ID: 20724948
[No Abstract] [Full Text] [Related]
31. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
Piccin A; Murphy C; Eakins E; Rondinelli MB; Daves M; Vecchiato C; Wolf D; Mc Mahon C; Smith OP
Eur J Haematol; 2019 Apr; 102(4):319-330. PubMed ID: 30664257
[TBL] [Abstract][Full Text] [Related]
32. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
33. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Kaul DK; Liu XD; Chang HY; Nagel RL; Fabry ME
J Clin Invest; 2004 Oct; 114(8):1136-45. PubMed ID: 15489961
[TBL] [Abstract][Full Text] [Related]
34. Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.
Silva Junior GB; Vieira AP; Couto Bem AX; Alves MP; Meneses GC; Martins AM; Araújo SM; Libório AV; Daher EF
Int J Clin Pharm; 2014 Aug; 36(4):766-70. PubMed ID: 24934760
[TBL] [Abstract][Full Text] [Related]
35. Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.
Jana S; Strader MB; Meng F; Hicks W; Kassa T; Tarandovskiy I; De Paoli S; Simak J; Heaven MR; Belcher JD; Vercellotti GM; Alayash AI
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385713
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease.
Khasabova IA; Gable J; Johns M; Khasabov SG; Kalyuzhny AE; Golovko MY; Golovko SA; Kiven S; Gupta K; Seybold VS; Simone DA
Haematologica; 2023 Mar; 108(3):859-869. PubMed ID: 35615929
[TBL] [Abstract][Full Text] [Related]
37. Most adults with severe HbSC disease are not treated with hydroxyurea.
Ghunney WK; Asare EV; Ayete-Nyampong JB; Oppong SA; Rodeghier M; DeBaun MR; Olayemi E
Blood Adv; 2023 Jul; 7(13):3312-3319. PubMed ID: 36799926
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.
Nath KA; Shah V; Haggard JJ; Croatt AJ; Smith LA; Hebbel RP; Katusic ZS
Am J Physiol Regul Integr Comp Physiol; 2000 Dec; 279(6):R1949-55. PubMed ID: 11080057
[TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.
Huang B; Ghatge MS; Donkor AK; Musayev FN; Deshpande TM; Al-Awadh M; Alhashimi RT; Zhu H; Omar AM; Telen MJ; Zhang Y; McMahon TJ; Abdulmalik O; Safo MK
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296435
[TBL] [Abstract][Full Text] [Related]
40. Urinary dysfunction in transgenic sickle cell mice: model of idiopathic overactive bladder syndrome.
Karakus S; Anele UA; Silva FH; Musicki B; Burnett AL
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F540-F546. PubMed ID: 31215803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
